RemeGen CFO Signals Strong Domestic Growth Following Q1 Results

RemeGen is doubling down on its domestic strategy as it reviews its first-quarter performance. CFO Shaojing Tong highlighted the company's commitment to scaling its operations within China, citing strong confidence in the domestic growth trajectory and the company's ability to capture local market share. The strategic focus comes at a time when Chinese biotech firms are navigating a complex regulatory and competitive landscape. By prioritizing the home market, RemeGen aims to solidify its commercial footprint and optimize its distribution channels before pursuing further expansion. Market data indicates that RemeGen has become a standout performer in its sector. Since the beginning of the year, the company's shares have outperformed all other constituents of the MSCI China Healthcare Index, reflecting strong investor confidence in its current trajectory. Investors are now monitoring whether the company can translate this stock momentum into sustained revenue growth. The CFO's optimistic outlook suggests a robust pipeline and the effective execution of the company's commercialization strategy within the region.